Stock Alert: Geron (GERN) Trades 7.44% Lower August 8

Equities Staff  |

Today, Geron Corp. (NASDAQ:GERN) was down $0.18 to close Monday at $2.24.

The company opened at $2.46 and shares fluctuated between $2.54 and $2.17 with 6,783,127 shares trading hands.

Geron is averaging 2,825,692 shares traded over the last 30 days. They have increased 98.36% YTD.

Geron anticipates its next earnings on 2022-08-15.

For technical charts, analysis, and more on Geron visit the company profile.

About Geron Corp.

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

To get more information on Geron Corp. and to follow the company's latest updates, you can visit the company's profile page here: Geron Corp.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

Bond Yields Have Risen Well Above Stock Dividend Yields. Are They a Buy?
We're at the Tail End of a Classic Video Game Stock Bust
Is Gold Really the Right Place for Your Money?
How Companies Can Succeed in AI Winter: Jeff Kagan

Market Movers

Sponsored Financial Content